Revolution Medicines, Inc. (RVMD) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Revolution Medicines, Inc. (RVMD) closed at USD 193.52 on 2026-10-14, a change of +232.7 % over the past year, with a market capitalization of USD 40.57B.
Revolution Medicines, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 193.52 |
| 2026-10-13 | 188.44 |
| 2026-10-12 | 193.95 |
| 2026-10-09 | 189.76 |
| 2026-10-08 | 188.12 |
| 2026-10-07 | 200.87 |
| 2026-10-06 | 199.87 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Revolution Medicines, Inc. key figures
- Previous close
- USD 193.52 (2026-10-14)
- 1-year change
- +232.7 %
- Market cap
- USD 40.57B
- Enterprise value
- USD 37.82B
- P/E ratio (trailing)
- -21.34
- P/E ratio (forward)
- -32.46
- EPS (trailing)
- -8.87
- EPS (forward)
- -5.83
- PEG ratio
- n/a
- Price to book
- 15.56
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 5.90
- Employees
- 883
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Revolution Medicines, Inc. and compare it with other stocks.
Analyze RVMDAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Revolution Medicines, Inc. shares.